α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Alpha-synuclein as therapeutic target in Parkinson's disease

Pathological pathway of α-synuclein aggregation. Abnormal misfolded

Alpha Synuclein – The Science of Parkinson's

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage

Pathological Pathways and Alpha-Synuclein in Parkinson's Disease: A View from the Periphery

Regulation of α-synuclein homeostasis and inflammasome activation by microglial autophagy

Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation: Molecular Therapy - Nucleic Acids

Zeroing in on neurodegenerative α-synuclein

Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease

Alpha-Synuclein aggregation HTRF kit

HTRF Phospho-A-Synuclein Ser129 aggregation

Current hypotheses for the involvement of a-synuclein in Parkinson's